Background. Today, there are many experimental studies on the study of mutations of the filaggrin gene (FLG) in atopic dermatitis (AD), determining the FLG level in the skin, but there are very few studies devoted to the study of the blood serum FLG level in this pathology. It is of interest to study the role of FLG in AD during pregnancy.
Objective. Evaluation of the serum FLG level in pregnant women with AD.
Methods. The single-arm, open-label clinical comparative prospective randomized controlled trial included 76 pregnant women with exacerbation of AD, 23 non-pregnant women with exacerbation of AD, 20 pregnant women without AD, and 20 non-pregnant women without AD. The AD severity was determined using the SCORAD index. The blood serum FLG level was determined by enzyme immunoassay.
Results. In pregnant women with exacerbation of AD, the FLG level was statistically significantly higher than in non-pregnant women with AD, pregnant and non-pregnant women without AD (Mann-Whitney test; p < 0.05). There was a moderate statistically significant relationship between the blood serum FLG level and the SCORAD index (R=0.653; p=0.001, direct relationship).
Conclusion. Pregnant women with AD exacerbation have high serum FLG levels, so FLG can be considered as an important biomarker for AD exacerbation during pregnancy. Further in-depth study of the role of FLG in the pathogenesis of AD during pregnancy will contribute to the formation of a more complete picture of the mechanism of development of dermatitis.

Keywords: SCORAD index, filaggrin, atopic dermatitis, pregnancy